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The risk of perinatal death and severe neonatal morbidity increases gradually after 41
weeks of pregnancy. Several randomised controlled trials (RCTs) have assessed if induc-
tion of labour (IOL) in uncomplicated pregnancies at 41 weeks will improve perinatal out-
comes. We performed an individual participant data meta-analysis (IPD-MA) on this
subject.
Methods and findings
We searched PubMed, Excerpta Medica dataBASE (Embase), The Cochrane Library,
Cumulative Index of Nursing and Allied Health Literature (CINAHL), and PsycINFO on Feb-
ruary 21, 2020 for RCTs comparing IOL at 41 weeks with expectant management until 42
weeks in women with uncomplicated pregnancies. Individual participant data (IPD) were
sought from eligible RCTs. Primary outcome was a composite of severe adverse perinatal
outcomes: mortality and severe neonatal morbidity. Additional outcomes included neonatal
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admission, mode of delivery, perineal lacerations, and postpartum haemorrhage. Prespeci-
fied subgroup analyses were conducted for parity (nulliparous/multiparous), maternal age
(<35/�35 years), and body mass index (BMI) (<30/�30). Aggregate data meta-analysis
(MA) was performed to include data from RCTs for which IPD was not available.
From 89 full-text articles, we identified three eligible RCTs (n = 5,161), and two contrib-
uted with IPD (n = 4,561). Baseline characteristics were similar between the groups regard-
ing age, parity, BMI, and higher level of education. IOL resulted overall in a decrease of
severe adverse perinatal outcome (0.4% [10/2,281] versus 1.0% [23/2,280]; relative risk
[RR] 0.43 [95% confidence interval [CI] 0.21 to 0.91], p-value 0.027, risk difference [RD]
−57/10,000 [95% CI −106/10,000 to −8/10,000], I2 0%). The number needed to treat (NNT)
was 175 (95% CI 94 to 1,267).
Perinatal deaths occurred in one (<0.1%) versus eight (0.4%) pregnancies (Peto odds
ratio [OR] 0.21 [95% CI 0.06 to 0.78], p-value 0.019, RD −31/10,000, [95% CI −56/10,000 to
−5/10,000], I2 0%, NNT 326, [95% CI 177 to 2,014]) and admission to a neonatal care unit
�4 days occurred in 1.1% (24/2,280) versus 1.9% (46/2,273), (RR 0.52 [95% CI 0.32 to
0.85], p-value 0.009, RD −97/10,000 [95% CI −169/10,000 to −26/10,000], I2 0%, NNT 103
[95% CI 59 to 385]). There was no difference in the rate of cesarean delivery (10.5% versus
10.7%; RR 0.98, [95% CI 0.83 to 1.16], p-value 0.81) nor in other important perinatal, deliv-
ery, and maternal outcomes. MA on aggregate data showed similar results.
Prespecified subgroup analyses for the primary outcome showed a significant difference
in the treatment effect (p = 0.01 for interaction) for parity, but not for maternal age or BMI.
The risk of severe adverse perinatal outcome was decreased for nulliparous women in the
IOL group (0.3% [4/1,219] versus 1.6% [20/1,264]; RR 0.20 [95% CI 0.07 to 0.60], p-value
0.004, RD −127/10,000, [95% CI −204/10,000 to −50/10,000], I2 0%, NNT 79 [95% CI 49 to
201]) but not for multiparous women (0.6% [6/1,219] versus 0.3% [3/1,264]; RR 1.59 [95%
CI 0.15 to 17.30], p-value 0.35, RD 27/10,000, [95% CI −29/10,000 to 84/10,000], I2 55%).
A limitation of this IPD-MA was the risk of overestimation of the effect on perinatal mortal-
ity due to early stopping of the largest included trial for safety reasons after the advice of the
Data and Safety Monitoring Board. Furthermore, only two RCTs were eligible for the IPD-
MA; thus, the possibility to assess severe adverse neonatal outcomes with few events was
limited.
Conclusions
In this study, we found that, overall, IOL at 41 weeks improved perinatal outcome compared
with expectant management until 42 weeks without increasing the cesarean delivery rate.
This benefit is shown only in nulliparous women, whereas for multiparous women, the inci-
dence of mortality and morbidity was too low to demonstrate any effect. The magnitude of
risk reduction of perinatal mortality remains uncertain. Women with pregnancies approach-
ing 41 weeks should be informed on the risk differences according to parity so that they are
able to make an informed choice for IOL at 41 weeks or expectant management until 42
weeks.
Study Registration: PROSPERO CRD42020163174
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Author summary
Why was this study done?
• Timely induction of labour (IOL) aims to prevent adverse outcomes. In observational
studies, although not usually in interventional studies, IOL has been associated with
increased risks of emergency cesarean delivery, uterine hyperstimulation, and uterine
rupture.
• The risk of stillbirth and several other serious perinatal and maternal complications
increases as the pregnancy continues beyond term.
• According to a recent meta-analysis (MA) on aggregate data from randomised con-
trolled trials (RCTs), perinatal mortality was lower after IOL at or beyond term com-
pared with a policy of expectant management. However, the upper limit of gestational
age for expectant management was not taken into account in this MA.
• The aim of this individual participant data meta-analysis (IPD-MA) was to compare the
effect of a management strategy of IOL at 41 weeks versus expectant management until
42 weeks on important perinatal and maternal outcomes of women with low-risk single-
ton pregnancies as well as to identify subgroups of women that could benefit from IOL
at 41 weeks.
What did the researchers do and find?
• Three RCTs including a total of 5,161 women with low-risk singleton pregnancies com-
paring IOL at 41 gestational weeks with expectant management until 42 gestational
weeks were identified.
• Data of two RCTs were available for inclusion in an IPD-MA with a total of 4,561
women.
• Overall, induction at 41 gestational weeks significantly reduced the composite outcome
of perinatal mortality and severe neonatal morbidity, and perinatal mortality alone,
without increasing the risk of cesarean delivery, operative vaginal delivery, perineal lac-
erations III and IV, or postpartum haemorrhage. However, the magnitude of the risk of
perinatal mortality remains uncertain.
• A prespecified subgroup analysis showed that the risk of composite severe adverse peri-
natal outcome in the IOL group was significantly decreased for nulliparous, but not for
multiparous women.
What do these findings mean?
• Women with pregnancies approaching 41 gestational weeks should be informed of the
benefits and risks of IOL at 41 weeks compared with expectant management until 42
weeks, with respect to the risk differences for nulliparous and multiparous women.
• Women can then make an informed choice regarding IOL at 41 weeks or awaiting
spontaneous onset of labour until 42 weeks.
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Introduction
When to induce labour in overdue pregnancies has been under debate since many years. The
risk of perinatal death and severe neonatal morbidity increases gradually after 41 weeks of
pregnancy with a steeper increase after 42 weeks [1,2]. The proportion of women reaching 41
weeks varies in high-income countries between 5% and 25% [3]. In 2018, 22% of women in
Sweden reached 41 weeks, and in the Netherlands, the rate was 16% [4,5].
Two randomised controlled trials (RCTs) recently evaluated the risk of adverse perinatal
outcome after a policy of induction of labour (IOL) at 41 weeks as compared with expectant
management until 42 weeks [6,7]. The first RCT concerns a non-inferiority trial among low-
risk women in the Netherlands (INDuction of labour at 41 weeks versus a policy of EXpectant
management until 42 weeks [INDEX]) comparing IOL at 41 weeks+0–1 days (41+0–1) with
expectant management until 42 weeks+0 days (42+0), in which non-inferiority of expectant
management was not proven [6]. The second RCT is a superiority trial from Sweden (SWEdish
Post-term Induction Study [SWEPIS]) comparing induction at 41+0–2 with expectant man-
agement until 42+0–1 in low-risk women. It was stopped early because of safety reasons. The
Data and Safety Monitoring Board recommended to stop the study owing to a higher perinatal
mortality in the expectant management group (no perinatal mortality in the IOL group and six
in the expectant management group). However, there was no significant difference in the pri-
mary outcome [7].
A Cochrane review from 2018 comparing birth outcomes after IOL or expectant manage-
ment concluded that a policy of IOL at or beyond term is associated with fewer adverse perina-
tal outcomes and fewer cesarean deliveries compared with expectant management, though the
absolute risk of perinatal death is small [8]. The conclusion is based on all included studies of
the systematic review, but a majority of the included trials had expectant management groups
that allows expectant management until far beyond 42 weeks, which could have influenced the
overall outcomes. The authors suggested that women could be helped in deciding on IOL or
expectant management by appropriate counselling (including information on absolute risks).
Further exploration of risk profiles of women was recommended as well as individual partici-
pant data meta-analysis (IPD-MA), which could help elucidate the role of specific factors, such
as parity, on outcomes of induction compared with expectant management. After results of
the current study were already finalised, an update of this Cochrane review was published in
which the main conclusion was similar as the previous version [9]. Although subgroup analysis
was performed for parity, this was not done for the 41 to 42 weeks’ comparison in this review.
A recently published systematic review including two RCTs, two quasi-experimental trials,
and three retrospective cohort studies compared IOL at 41+1 to 41+6 weeks with expectant
management until 42+0 to 42+6 weeks. IOL at 41+1 to 41+6 weeks was found to be associated
with an increased risk of cesarean delivery and pH <7.10, but it lacked power to estimate the
risk of perinatal mortality [10]. However, the time frame in this systematic review allows com-
parison beyond 41 weeks with expectant management until 43 weeks, which is not comparable
with our time frame. We chose an upper limit of 42 weeks because continuing pregnancy after
42 weeks is no longer regular policy since many years due to its association with increased
perinatal mortality. This is reflected in many national and international guidelines [11–15].
Furthermore, nonexperimental studies without clear randomisation procedure are prone for
selection bias. Also, we aimed to evaluate outcomes of intended management strategies, not
actual start of labour, because women have to decide on a management strategy before they
know if and when they will go into spontaneous onset of labour. For this reason, we only
included RCTs in our IPD-MA.
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Sample sizes of RCTs are typically insufficient to estimate the risk for rare outcomes like
perinatal mortality and severe morbidity. Exploring potential subgroup effects of maternal age,
parity, body mass index (BMI), or fetal sex is therefore impossible in individual trials. IPD-MA
increases power and has the advantage to allow investigation of interactions between interven-
tion and participant characteristics in the total RCT population as well as in subgroups [16].
The objective of the IPD-MA was to evaluate the effect of IOL at 41 weeks versus expectant
management until 42 weeks on perinatal and maternal outcomes, with a focus on rare adverse
perinatal outcomes. We also aimed to assess whether treatment effects differed in subgroups.
Methods
The protocol for this IPD-MA was registered on PROSPERO (2020; CRD42020163174) and is
available at https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=163174. The
IPD-MA is reported according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA)-IPD guidelines; see S1 Text PRISMA checklist [17].
Data from the INDEX trial were pseudo-anonymised. A code was generated for each partic-
ipant, and the key to the personal data is stored in the archives of the participating midwifery
practices and hospitals. Data in the SWEPIS trial were not anonymised. All data in the merged
database were fully anonymised. A collaboration group from the SWEPIS and INDEX project
teams conducted the study.
Ethics statement
RCTs included in the IPD-MA had received country specific ethical approval for the study,
and each participant gave informed written consent. Details can be found in the original
manuscripts. Specific ancillary approval for the use of individual patient data for the purpose
of this meta-analysis (MA) was given by the Medical Ethical Committee of Amsterdam
UMC-AMC (Dnr W20_225#20.259, May 20, 2020) for reuse of data from the INDEX trial and
from the SWEPIS trial by the Swedish Ethical Review Authority (Dnr 285–14, amendment
2019–04094, August 5, 2019).
Specific objectives
The objectives of the IPD-MA were to apply IPD-MA methodology to assess the effect on perina-
tal and maternal outcomes, with a focus on rare adverse perinatal outcomes, after IOL at 41 weeks
compared with expectant management until 42 weeks in women with low-risk singleton pregnan-
cies and to identify possible subgroups that might benefit from IOL at 41 weeks. For this reason,
the effect of the intervention was analysed for prespecified subgroups of participant characteristics:
maternal age, parity, and BMI. In addition, a post hoc analysis on fetal sex was carried out.
Eligibility criteria
RCTs were included if a strategy of IOL at 41+0–2 was compared with a strategy of expectant
management with various regimes of fetal surveillance and induction at 42+0–1 in low-risk
women with an uncomplicated singleton pregnancy. Perinatal mortality, neonatal, and mater-
nal morbidity had to be reported. Only RCTs were eligible. Cluster-randomised RCTs and
quasi-random design studies were not considered.
Study identification: Information sources and search strategy
We performed a systematic literature search in PubMed, Excerpta Medica dataBASE
(Embase), The Cochrane Library, Cumulative Index of Nursing and Allied Health Literature
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(CINAHL), and PsycINFO (EBSCOhost Research Databases). Our search was a continuation
of a systematic literature search made in the context of a Health Technology Assessment
(HTA) report in 2012 exploring the same research question but with a wider inclusion crite-
rion than in this paper [18]. UBW, HH, and CB authored this report. The searches comprised
the time period from database inception to February 21, 2020. Reference lists of relevant arti-
cles were scrutinised for additional references. The detailed search strategy is presented in the
Supporting information (S2 Text). We searched Clinicaltrials.gov and the World Health Orga-
nization’s International Clinical Trials Registry Platform databases for ongoing and unpub-
lished RCTs. We used no limitation for publication year or language.
Study selection processes
Two HTA librarians carried out a first selection of eligible RCTs. Potential eligible RCTs were
scrutinised independently by two teams (MA, HH, and UBW and JKJK, JCK, and EdM). Eligi-
bility of RCTs was decided on at a consensus meeting.
Data collection process and data items
Corresponding authors of eligible RCTs were contacted and invited to participate and provide
data to the IPD-MA.
Prespecified variables and outcomes were discussed and defined by the authors. Study-level
and participant-level data were scrutinised on the proportion of missing variables and data.
The definitions of variables and outcomes were compared and harmonised. If a definition did
not correspond, a new definition was agreed upon. In case of neonatal complications, e.g.,
meconium aspiration syndrome (MAS), intracranial bleeding, and neonatal infection/sepsis,
we took advice from neonatologists and based the definition on the International Classifica-
tion of Diseases 10th Revision (ICD-10) description [19].
IPD were collected on all randomised women. These included baseline data for descriptive
purpose and analyses, date of randomisation, gestational age at randomisation, date of deliv-
ery, and data on primary and secondary outcomes. Data were checked for extreme or missing
values and consistency with published data. The IPD was collected by one of the statisticians
(MM), who managed the data and merged all data into one anonymised IPD-MA dataset. The
IPD-MA dataset was stored in a secure database accessible only by the two statisticians (MM
and RGD).
IPD integrity
Sequence generation, data accuracy, data consistency and completeness, frequencies, and pos-
sible baseline imbalances of all outcomes used in this IPD analysis were checked by statisticians
and authors of the included RCTs.
Study quality including risk of bias assessment
We used the risk of bias tool developed by Cochrane to assess the risk of bias for each study
[20]. Risk of bias was assessed independently by some authors (MA, HH, and UBW and JKJK,
JCK, and EdM), and disagreement was resolved by discussion. Each study was evaluated for
adequacy of randomisation (selection bias), blinding for participants and personnel and statis-
tician responsible for analysis (performance bias), blinding of outcome assessment (detection
bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other
bias (conflict of interest). Each risk of bias was rated as either low, unclear, moderate, or high
for the RCT.
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Two individual teams (MA, UBW, and HH and JKJK, JCK, and EdM, respectively) evalu-
ated external validity, internal validity (risk of bias/study limitations), and precision for each
study.
Specification of outcomes and effect measures
The primary outcome “severe adverse perinatal outcome” was a composite of perinatal mortal-
ity and severe neonatal morbidity. Perinatal mortality was defined as stillbirth or neonatal
mortality of live births with death between day 0 and 28 (deaths due to accidents were
excluded). Severe neonatal morbidity was a composite of (1) five-minute Apgar score <4 (as
an Apgar score <4 at five minutes is associated with an increased risk on long-term adverse
neonatal outcome [21]); (2) hypoxic ischemic encephalopathy II-III (asphyxia/encephalopathy
in need of therapeutic cooling); (3) intracranial haemorrhage (intracranial or intraventricular
haemorrhage based on radiological findings with ultrasound of the brain, computed tomogra-
phy, or magnetic resonance imaging); (4) neonatal convulsions (seizures with electroencepha-
lography [EEG]/amplitude EEG confirmation, seizures without EEG/amplitude EEG
confirmation, and silent seizures [EEG/diagnosis]); (5) MAS (respiratory distress after birth in
the presence of meconium stained amniotic fluid with need of mechanical ventilation); (6)
mechanical ventilation within the first 72 hours (with laryngeal tube and ventilator machine);
and/or (7) obstetric brachial plexus injury.
Secondary perinatal outcomes consisted of all individual components of the composite out-
come separately including stillbirth and neonatal mortality. Additional secondary outcomes
were the composite outcome with five-minute Apgar<7 instead of Apgar<4, admission to
neonatal care (medium care—excluding observation only for protocol—or intensive care
unit), admission to neonatal care�4 days mimicking more intensified neonatal care for sick
infants in need for longer treatment and/or more extensive observation (neonatal intensive
care unit [NICU] admission as such could not be used as a variable due to different admission
criteria in Sweden and the Netherlands), mean birthweight, small for gestational age (SGA)
according to national birthweight curves (<10th percentile and<3rd percentile) [22,23],
macrosomia (�4,500 g), five-minute Apgar score<7, infection/sepsis (clinical suspected find-
ings or proved positive blood culture and antibiotic treatment), meconium stained amniotic
fluid, humerus fracture, and congenital anomalies (any congenital anomalies after excluding
minor congenital anomalies according to the European Surveillance of Congenital Anomalies
[EUROCAT]) [24].
Secondary maternal outcomes included interval from randomisation to delivery, gesta-
tional age at time of delivery, onset of labour (spontaneous or IOL), oxytocin during labour
(for IOL and/or augmentation), pain treatment during vaginal delivery (epidural anaesthe-
sia/spinal anaesthesia/opiates), mode of delivery (spontaneous vaginal delivery, assisted vagi-
nal delivery, or cesarean delivery with indication for intervention), episiotomy, perineal
lacerations III and IV, postpartum haemorrhage (>1,000 ml and >2,000 ml), fever during
labour (�38˚C), antibiotics during labour (prophylaxis or therapy), manual removal of pla-
centa (with or without haemorrhage >1,000 ml), hypertensive disorders of pregnancy
including eclampsia and HELLP syndrome (haemolysis, elevated liver enzymes, and a low
platelet count), maternal deep vein thrombosis or pulmonary embolism, admission to inten-
sive care unit, and maternal death up to 42 days after delivery (deaths due to accidents
excluded).
Outcomes were analysed as relative risks (RRs) and risk differences (RDs; expressed per
10,000 patients). For major outcomes, the number needed to treat (NNT) was provided as
well.
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Synthesis methods and data analysis
General baseline characteristics were presented as frequencies with percentages, means, and
standard deviations or medians with interquartile ranges (IQRs).
Individual participant data meta-analysis
One-step MA was done for those outcomes where IPD could be used. For dichotomous out-
comes, RR and RD were estimated using generalised linear models with a log- or identity-link
and binomial distribution, respectively. A categorical covariable coding for the study was used
to permit for within-study associations. For all risk estimates, a 95% confidence interval (CI)
and p-value were calculated.
In case of a zero-event outcome in one arm of one or both trials, Peto odds ratios (ORs)
were calculated using a two-step approach [25]. In case of zero events in both arms (double
zero events) in all but one RCT, no risk estimates or inferential statistics were calculated
because double zero events will add zero weight to the IPD-MA. Continuity correction for
sparse events was not used.
For continuous outcomes, the mean difference was estimated with 95% CI using a general
linear model, also with a categorical covariable coding for study. Chi-squared test was used for
non-ordered categorical variables.
All randomised women with outcome data were included in the final analyses. Outcomes
were analysed on an intention-to-treat (ITT) basis according to the treatment allocated by ran-
domisation comparing IOL at 41+0–2 to expectant management until 42+0–1.
Heterogeneity between trials was explored by calculating the I2 and p-value estimates of var-
iability. Values of I2�50% were considered to indicate meaningful heterogeneity. Due to the
low number of eligible RCTs, funnel plots for assessment of publication bias were not used.
Application of meta-regression to explain heterogeneity was not possible for outcomes ana-
lysed by two-step analysis. NNT for benefit with 95% CI was calculated as the inverse of the
absolute risk reduction (ARR): 1/ARR.
In order to assess whether the effect of the intervention differed by prespecified subgroups,
analyses were conducted for parity (nulliparous and multiparous), maternal age (<35 years
and�35 years), and BMI (<30 and�30). In addition, a post hoc subgroup analysis on fetal
sex was performed. A test for multiplicative interaction between intervention and maternal
characteristics was performed by means of an interaction term in the regression model to
examine whether intervention effects differed between subgroups. An interaction with a p-
value <0.05 was considered to indicate that the effect of intervention differed between sub-
groups. Subgroup analyses were only performed on the primary composite outcome and the
selected secondary outcomes perinatal mortality and cesarean delivery. In case of significant
interaction for any of these outcomes, additional analysis was performed on all outcomes for
this subgroup.
Meta-analysis on aggregate data
If IPD was not available, MA was performed on aggregate data from eligible trials. In this situa-
tion, RRs were calculated using a Mantel–Haenszel fixed effect model, or Peto ORs were calcu-
lated as appropriate.
Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina,
United States). Review Manager (RevMan, Computer program. Version5.3. Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used to conduct the MA on
aggregate data.
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Results
Study selection and IPD obtained
The updated literature search resulted in 1,111 articles after removal of duplicates. Another 20
RCTs were added from the former HTA report from 2012 [18]. All articles were screened on
title and abstract. We assessed 89 full-text articles, of which three RCTs published between
2005 and 2019 were eligible for IPD-MA (n = 5,161 participants), the Gelisen and colleagues
trial, the INDEX trial, and the SWEPIS trial (Fig 1) [6,7,26].
Eight RCTs were identified in the ongoing RCT search, of which one was relevant for our
IPD-MA and is expected to run until September 2022 (ISRCTN 83219789, “The Finnish ran-
domised controlled multicentre trial on optimal timing of labour induction in nulliparous
women with post-term pregnancy”). Four RCTs were already published, and three were not
relevant for our research question due to deviating intervention, comparison group, or gesta-
tional age.
The corresponding authors in each eligible RCT were contacted in order to participate in
the IPD-MA. The corresponding author from the Gelisen and colleagues trial replied that they
could not participate in the IPD-MA because the original database was not available anymore.
We therefore conducted an MA on aggregate data available in all three RCTs for outcomes
with similar definitions and relevance for this research question. In total, the three RCTs
included 5,161 women, (n = 600 from the Gelisen and colleagues trial, n = 1,801 from the
INDEX trial, and n = 2,760 from the SWEPIS trial): 2,581 women were assigned to IOL, and
2,580 to expectant management. Two of 3 RCTs contributed data for the IPD-MA (the
INDEX and SWEPIS RCTs). Hence, the IPD-MA included 4,561 women: 2,281 women were
assigned to IOL and 2,280 to expectant management.
Study characteristics
The characteristics of the included RCTs are shown in Table 1.
All three trials included low-risk singleton pregnancies with fetus in cephalic position and
had previous cesarean delivery or other major uterine surgery as an exclusion criterion. In the
two trials included in the IPD-MA, fetal surveillance in the expectant management group was
performed according to local protocol (Table 1).
In Table 2, the baseline characteristics of the population included in the IPD-MA are
shown. Baseline characteristics were similar between the IOL and expectant management
group. Heterogeneity between the two included RCTs was found for parity and educational
level. In SWEPIS, 55.2% (762/1,381) of the IOL group were nulliparous versus 54.6% (753/
1,379) in the expectant management group. In the INDEX trial, 50.8% (457/900) in the IOL
group were nulliparous compared to 56.7% (511/907) in the expectant management group (S1
Table). In SWEPIS, 64.6% (789/1,275) of women in the IOL group and 62.8% (780/1,242) in
the expectant management group had education on university or similar level. In the INDEX
trial, the distribution was 31.8% (286/900) versus 35.7% (322/901) (S1 Table).
IPD integrity
There were no important issues concerning outcome data identified in checking IPD in the
two participating RCTs (S2 Table). A few secondary outcomes showed different proportions
between the RCTs, e.g., admission to NICU and neonatal medium care, neonatal infection,
and use of antibiotics during labour. For NICU admission, the indications for admittance
were not comparable in both RCTs resulting in an imbalance for NICU admission. Therefore,
a new variable was defined for both studies: “admission to neonatal care�4 days” as proxy for
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infants in need for longer treatment and more extensive monitoring. Regarding the imbalance
of neonatal infection, the INDEX trial included suspected infection in their outcome, and it was
not possible to distinguish the true infections from the suspected ones. A plausible explanation
for the discrepancy regarding maternal use of antibiotics during labour (significantly more in
the SWEPIS trial) could be the difference in use of epidural anaesthesia, which is associated
with fever and different policies regarding prophylactic treatment for group B streptococcus.
Study quality including risk of bias assessment
Risk of bias within RCTs is presented in Table 3. The two RCTs included in the IPD-MA
mostly had low risk of bias. In the Gelisen and colleagues trial, the risk of selection, detection,
Fig 1. PRISMA IPD flowchart of literature search. HTA, Health Technology Assessment; IPD, individual participant data; PICO, patients,
intervention, comparison, outcome; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomised controlled
trial.
https://doi.org/10.1371/journal.pmed.1003436.g001




Gelisen et al. 2005 Turkey Keulen et al. 2019 The INDEX trial the
Netherlands
Wennerholm et al. 2019 The SWEPIS trial
Sweden




Participants 600 women with a Bishop score less than 5 (300
in IOL group and 300 in EM group)
1,801 women regardless of Bishop score (900 in
the IOL group and 901 in the EM group)
2,760 women regardless of Bishop score (1,381
in the IOL group and 1,379 in the EM group).
The RCT was planned to recruit 10,038
women, 5,019 in each arm. The RCT was
stopped in advance due to safety reasons (6
perinatal deaths in EM group versus 0 in IOL
group)
Intervention IOL at 41+0–1 (three arms): (1) induction with
50-μg vaginal misoprostol (n = 100); (2)
induction with transvaginal Foley balloon
(n = 100); and (3) induction with infusion of
oxytocin (n = 100) compared with EM until 42
+0. IOL method: 50-μg vaginal misoprostol.
Fetal surveillance in the EM group: a nonstress
cardiotocography test and amniotic fluid
measurement twice weekly. In addition, a
biophysical scoring on a single occasion three to
five days after randomisation
IOL at 41+0–1 compared with EM until 42+0.
IOL method in both groups according to local
protocol, e.g., prostaglandin E1 (oral or
vaginal), prostaglandin E2, Foley catheter or
double-balloon catheter, or a combination of
them and/or amniotomy. Fetal surveillance in
the EM group was performed according to local
protocols and could include cardiotocography
and/or an ultrasound assessment of amniotic
fluid
IOL at 41+0–2 compared with EM until 42+0–
1. IOL method in both groups according to
local management, e.g., prostaglandin E1 (oral
or vaginal), prostaglandin E2, Foley catheter
or double-balloon catheter, or a combination
of them and/or amniotomy. Fetal surveillance
in the EM group was performed according to
local protocols and typically included
antenatal visits with auscultation of the fetal
heart rate
Primary outcome Cesarean delivery rate, length of hospital stay,
and neonatal outcomes (i.e., rate of
macrosomia, incidence of meconium stained
amniotic fluid, arterial cord blood pH <7.16,
and rate of admission to NICU)
A composite of stillbirth, neonatal death until
28 days, Apgar<7 at five minutes and/or an
arterial umbilical cord pH <7.05 and/or MAS
and/or obstetric plexus brachialis injury and/or
intracranial haemorrhage and/or NICU
admission
A composite of stillbirth, neonatal death until
28 days, Apgar <7 at five minutes and/or an
arterial umbilical cord pH <7.00 or metabolic
acidosis (pH <7.05 and base deficit >12
mmol/L) and/or hypoxic ischaemic
encephalopathy grades I–III and/or
mechanical ventilation within 72 hours and/or
intracranial haemorrhage, and/or convulsions
and/or MAS and/or obstetric brachial plexus
injury
Follow-up Until discharge from the hospital The neonates were followed until 28 days and
the women 42 days postpartum regarding
mortality. All other outcomes were followed
until discharge from the hospital
The neonates were followed until 28 days and
the women 42 days postpartum regarding
mortality. All other outcomes were followed
until discharge from the hospital
EM, expectant management; INDEX, INDuction of labour at 41 weeks versus a policy of EXpectant management until 42 weeks; IOL, induction of labour; MA, meta-
analysis; MAS, meconium aspiration syndrome; NICU, neonatal intensive care unit; RCT, randomised controlled trial; SWEPIS, SWEdish Post-term Induction Study.
https://doi.org/10.1371/journal.pmed.1003436.t001
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and reporting bias was unclear. In this RCT, published in 2004, sealed opaque envelopes were
used for randomisation, the randomisation sequence process was not reported, and the study
protocol was not published, which is all according to the standards at the time. All three RCTs
had some risk of performance bias due to lack of blinding of participants and clinical person-
nel. In addition, the Gelisen and colleagues trial did not report if the assessment was blinded
or not. In the INDEX trial, the statisticians who performed the analyses were blinded, but in
the SWEPIS trial, they were not.
The Gelisen and colleagues trial had some or major problems regarding external validity
and precision. The sample size was too small for detection of severe adverse perinatal out-
comes. The INDEX trial had minor problems with external validity due to the low inclusion
rate of eligible women (30%). The external validity was good to its own setting. Obstetric care
in the Netherlands is divided into primary care (pregnancy and delivery of low-risk women
supervised by a community midwife with delivery at home or in the hospital) and secondary
care (pregnancy and delivery supervised by clinical midwives and obstetricians), which was
reflected in the RCT. The RCT had no problems with precision for the primary outcome.
The SWEPIS trial had minor problems concerning external validity. There was a lower
inclusion rate than expected (22% of eligible women), but compared to the background popu-
lation, there were only small deviations including a higher rate of women with university
Table 2. Baseline characteristics of the population included in the individual patient data MA.
Variable IOL group (n = 2,281) EM group (n = 2,280)
Maternal age at randomisation (years) n = 2,281 n = 2,280
Mean (standard deviation) 31.0 (4.8) 30.7 (4.6)
Age�35 479 (21.0) 431 (18.9)
Parity (includes stillbirths and live births) n = 2,281 n = 2,280
Nulliparous 1,219 (53.4) 1,264 (55.4)
Multiparous 1,062 (46.6) 1,016 (44.6)




Mean (standard deviation) 24.8 (4.6) 25.1 (4.8)
BMI�30 246 (11.4) 301 (14.0)




Values are numbers (percentages) unless stated otherwise.
� Information on all participants was not available.
BMI, body mass index; EM, expectant management; IOL, induction of labour; MA, meta-analysis.
https://doi.org/10.1371/journal.pmed.1003436.t002
Table 3. Risk of bias within individual RCTs.
Author Gelisen et al. INDEX trial SWEPIS trial
Selection bias Unclear Low Low
Performance bias High� Moderate� High�
Detection bias Unclear Low Low
Attrition bias Low Low Low
Reporting bias Unclear Low Low
Conflict of interest bias Low Low Low
� The lack of blinding in all RCTs is due to the nature of intervention, i.e., it is not possible to blind the participants and staff.
INDEX, INDuction of labour at 41 weeks versus a policy of EXpectant management until 42 weeks; RCT, randomised controlled trial; SWEPIS, SWEdish Post-term
Induction Study.
https://doi.org/10.1371/journal.pmed.1003436.t003
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education. In addition, the internal validity of the estimated risk for perinatal mortality can be
affected by the early termination of the trial following advice from its Data and Safety Monitor-
ing Board. The board recommended stopping for safety after an increased risk for perinatal
mortality was observed at a planned interim analysis. Early termination of an RCT is associ-
ated with overestimating of the treatment effect, especially for events with low occurrence [27].
There were no or minor problems regarding study limitation for the other outcomes. Regard-
ing precision, the study had lower power than planned for the composite outcome and perina-
tal mortality due to the early stopping.
Primary outcome
In this IPD-MA, there was a significant difference in the primary composite outcome, in
favour of the IOL group with 0.4% (10/2,281) compared to the expectant management group
with 1.0% (23/2,280); (RR 0.43 [95% CI 0.21 to 0.91], p-value 0.027, RD −57/10,000 [95% CI
−106/10,000 to −8/10,000], I2 0%) (Table 4). NNT was 175 (95% CI 94 to 1,267).
Perinatal secondary outcomes
In Table 4, the perinatal outcomes are presented. Perinatal mortality was significantly lower in
the IOL group with 0.04% (1/2,281) versus 0.35% (8/2,280) in the expectant management
group (Peto OR 0.21 [95% CI 0.06 to 0.78], p-value 0.019, RD −31/10,000 [95% CI −56/10,000
to −5/10,000], I2 0%). NNT was 326 (95% CI 177 to 2,014).
The only perinatal death in the IOL group was a stillbirth that occurred one day after rando-
misation but before IOL. In the expectant management group, seven of the eight deaths were
stillbirths and one baby died due to hypoxic ischemic encephalopathy. In postmortem exami-
nation of one of the stillbirths, a nonlethal cardiovascular malformation was found and two of
the stillbirths were SGA (both between the 5th and 10th centiles). In the other six cases, no
possible explanation was found.
Aggregate data MA on perinatal mortality of the three RCTs (n = 5,161 infants) showed
similar results (S1 Fig). Since both included RCTs in the IPD-MA had a primary outcome with
Apgar <7 instead of Apgar <4 at five minutes, we also calculated RR and RD for the primary
outcome with Apgar <7. The primary outcome including Apgar <7 occurred in 1.5% (34/
2,281) in the IOL group versus 2.3% (52/2,281) in the expectant management group (RR 0.65
[95% CI 0.43 to 1.00], p-value 0.051, RD −79/10,000 [95% CI −158/10,000 to 0], I2 13%).
Admittance to neonatal care unit for four days or longer was significantly lower in the IOL
group compared with the expectant management group (1.1% [24/2,280] versus 2.0% [46/
2,273], p-value 0.009, RR 0.52 [95% CI 0.32 to 0.85], RD −97/10,000 [95% CI −169/10,000 to
−26/10,000], I2 0%). NNT was 103 (95% CI 59 to 385). There were fewer neonates with macro-
somia (�4,500 g) than in the expectant management group (3.9% [92/2,281] versus 6.7% [155/
2,280], RR 0.59 [95% CI 0.46 to 0.76], p-value <0.001, RD −278/10,000 [95% CI −409/10,000
to −147/10,000], I2 0%). No significant differences were found in other perinatal secondary
outcomes.
Delivery outcomes
Table 5 summarises the delivery outcomes for the IPD-MA. The median gestational age in the
IOL group was 288 (IQR 287; 289) days and 291 (IQR 289; 293) in the expectant management
group, which corresponds with 41+1 versus 41+4 weeks, a difference of three days. In the IOL
group, 79.8% (1,821/2,281) of the women were induced while the birth process started sponta-
neously in 19.9% (455/2,281 women). In the expectant management group, 30.4% (694/2,280)
of the women were induced, while labour started spontaneously in 69.5% (1,584/2,280). In the
PLOS MEDICINE Induction of labour at 41 weeks or expectant management until 42 weeks
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003436 December 8, 2020 13 / 25
Table 4. Perinatal outcomes in the population included in the IPD-MA.
Variable IOL group (n = 2,281) EM group (n = 2,280) RR or Peto
OR (95% CI)
p-value Difference between groups




Primary outcome n = 2,281 n = 2,280
Primary composite outcome� 10 (0.4%) 23 (1.0%) 0.43 (0.21; 0.91)† 0.027 −57 (−106; −8) 0 0.40
Subcomponents of primary composite outcome n = 2,281 n = 2,280
Perinatal mortality‡ 1 (0.0) 8 (0.4) 0.21 (0.06; 0.78)# 0.019 −31 (−56; −5) 0 0.34
Stillbirth 1 (0.0) 7 (0.3) 0.22 (0.06; 0.89)# 0.034 −26 (−51; −2) 0 0.36
Subcomponents of primary composite outcome n = 2,280 n = 2,273
Neonatal mortality (live births with mortality
<28 days)
0 (0.0) 1 (0.0) NE NE NE NE NE
Apgar score <4 at 5 minutes of live births 3 (0.1) 4 (0.2) 0.75 (0.17; 3.30)# 0.70 −4 (−27; 18) 74 0.05
HIE II-III 2 (0.1) 3 (0.1) NE NE NE NE NE
Intracranial haemorrhage 1 (0.0) 2 (0.1) NE NE NE NE NE
Neonatal convulsions 1 (0.0) 3 (0.1) NE NE NE NE NE
MAS 2 (0.1) 5 (0.2) 0.42 (0.10; 1.86)# 0.25 −13 (−36; 10) 0 1.00
Mechanical ventilation with tracheal intubation
within the first 72 hours
4 (0.2) 9 (0.4) 0.44 (0.14; 1.44)† 0.18 −22 (−53; 9) 0 0.51
Obstetric brachial plexus injury 4 (0.2) 1 (0.0) NE NE NE NE NE
Additional secondary neonatal outcome n = 2,280 n = 2,273
Composite outcome with Apgar<7 at 5 minutes
instead of <4
34/2,281 (1.5) 52/2,280 (2.3) 0.65 (0.43; 1.00)† 0.051 −79 (−158; −0) 13 0.28
Admittance to a neonatal care unit§ 79 (3.5) 109 (4.8) 0.72 (0.54; 0.96)† 0.024 −133 (−249; −18) 0 0.38
Admission to a neonatal care unit �4 days 24 (1.1) 46 (1.9) 0.52 (0.32; 0.85)† 0.009 −97 (−163; −26) 0 0.35
Neonatal infection or sepsis¶ 49 (2.1) 59 (2.6) 0.83 (0.57; 1.21) 0.33 −44 (−132; 44) 52 0.15
Apgar score <7 at 5 minutes of live births 29 (1.3) 39 (1.7) 0.74 (0.46; 1.19) 0.22 −44 (−115; 26) 66 0.09
Humerus fracture 0/2,281 (0.0) 1/2,280 (0.0) NE NE NE NE NE
Birth weight (g) n = 2,281 n = 2,280
Mean (standard deviation) 3,764 (417) 3,823 (439) <0.001 −58.6 (−83.5; −33.8)
Macrosomia (�4,500 g) 92 (3.9) 155 (6.7) 0.59 (0.46; 0.76)† <0.001 −278 (−409; −147) 0 0.97
SGA||
<3rd percentile 37 (1.6) 45 (2.0) 0.82 (0.54; 1.27) 0.38 −35 (−112; 42) 83 0.01
<10th percentile 169 (7.4) 188 (8.2) 0.90 (0.74; 1.10)† 0.29 −84 (−239; 72) 0 0.88
Congenital anomaly�� 30 (1.3) 36 (1.6) 0.83 (0.52; 1.35)† 0.46 −26 (−96; 43) 0 0.96
Boy 1,228 (53.8) 1,194 (52.4) 1.03 (0.97; 1.09)† 0.31 146 (−143; 435) 0 0.87
Values are numbers (percentages) unless stated otherwise. RR is adjusted for RCT. p-value corresponds to the method used to calculate the RR/OR.
� Including perinatal mortality, Apgar<4 at 5 minutes, HIE II-III, intracranial haemorrhage, neonatal convulsions, MAS, obstetric brachial plexus injury, and
mechanical ventilation within 72 hours.
† Adjusted RR.
‡ Stillbirth and neonatal mortality (live births with mortality <28 days).
# Peto OR.
§ Neonates admitted only for routine observation excluded.
¶ In the INDEX trial, neonates with suspected infection are included.
|| According to national gestational and sex-specific references [22,23].
�� Minor birth anomalies according to EUROCAT excluded [24].
CI, confidence interval; EM, expectant management; EUROCAT, European Surveillance of Congenital Anomalies; HIE, hypoxic ischemic encephalopathy; INDEX,
INDuction of labour at 41 weeks versus a policy of EXpectant management until 42 weeks; IOL, induction of labour; IPD-MA, individual participant data meta-analysis;
MAS, meconium aspiration syndrome; NE, not estimated due to 0 events in both arms in 1 or both trials; OR, odds ratio; RCT, randomised controlled trial; RD, risk
difference; RR, relative risk; SGA, small for gestational age.
https://doi.org/10.1371/journal.pmed.1003436.t004
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IOL group, 0.2% of the women (5/2,280) versus 0.1% (2/2,281) in the expectant management
group had a scheduled cesarean delivery.
In addition, aggregate data MA of the three RCTs (n = 5,161 women) showed no difference
in the frequency of cesarean delivery (S2 Fig).
In the IOL group, the presence of meconium-stained amniotic fluid was lower than in the
expectant management group (17.8% [380/2,138] versus 25.9%, [525/2,028] RR 0.68 [95% CI
0.61 to 0.77], p-value< 0.001, RD −821/10,000 [95% CI −1,070/10,000 to −572/10,000], I2 0%).
The rate of MAS in the IOL group was 0.1% (2/2,280) and 0.2% (5/2,273) in the expectant
management group, RR 0.42 (0.10 to 1.86), p-value 0.25, RD −13/10,000 (−36/10,000 to 10/
10,000), I2 0%. The use of oxytocin was higher in the IOL group compared to the expectant
management group (63.1% [1,440/2,281] versus 47.2% [1,077/2,280], RR 1.33 [95% CI 1.26
Table 5. Delivery outcomes in the population included in the IPD-MA.
Variable IOL group (n = 2,281) EM group (n = 2,280) RR (95% CI) p-value Difference between groups




Gestational age at delivery (days) n = 2,281 n = 2,280
Median (IQR) 288 (287; 289) 291 (289; 293) <0.001
Time from randomisation to delivery (days) n = 2,281 n = 2,280
Mean (standard deviation) 1.88 (1.49) 4.47 (2.81) <0.001 −2.59 (−2.72; −2.46)
Onset of delivery n = 2,281 n = 2,280 <0.001
Spontaneous 455 (19.9) 1,584 (69.5)
Induction 1,821 (79.8) 694 (30.4)
Scheduled cesarean delivery 5 (0.2) 2 (0.1)
Meconium stained amniotic fluid 380/2,138 (17.8) 525/2,028 (25.9) 0.68 (0.61; 0.77) <0.001 −821 (−1,070; −572) 0 0.52
Use of oxytocin� 1,440/2,281 (63.1) 1,077/2,280 (47.2) 1.33 (1.26; 1.40) <0.001 1,589 (1,305; 1,872) 89 0.002
Mode of delivery n = 2,281 n = 2,280
Spontaneous vaginal delivery 1,860 (81.5) 1,836 (80.5) 1.01 (0.98; 1.04) 0.41 101(−126; 328) 0 0.65
Cesarean delivery 240 (10.5) 245 (10.7) 0.98 (0.83; 1.16) 0.81 −22 (−201; 157) 0 0.83
Operative vaginal delivery 181 (7.9) 199 (8.7) 0.91 (0.75; 1.10) 0.33 −79 (−239; 81) 0 0.56
Indication for cesarean delivery n = 240 n = 245 0.34¶
Failure to progress‡ 120 (50.0) 122 (49.8)
Suspected fetal distress 65 (27.0) 57 (23.3)
Suspected fetal distress and
failure to progress
17 (7.1) 21 (8.6)
Failed operative vaginal delivery 13 (5.4) 24 (9.8)
Other§ 25 (10.4) 21 (8.6)
Indication for operative vaginal delivery n = 181 n = 199 0.24¶
Failure to progress| 89 (49.2) 98 (49.2)
Fetal distress 76 (42.0) 71 (35.7)
Fetal distress and failure to
progress
15 (8.3) 29 (14.6)
Maternal complication 1 (0.6) 1 (0.5)
Values are numbers (percentages) unless stated otherwise. RR is adjusted for trial.
� Both induction and/or labour augmentation.
‡ Including failed induction.
§ Including scheduled due to, e.g., undetected breech or transverse presentation/maternal indication.
¶ Chi-squared test.
| Including maternal distress.
CI, confidence interval; EM, expectant management; IOL, induction of labour; IPD-MA, individual participant data meta-analysis; IQR, interquartile range; RD, risk
difference; RR, relative risk.
https://doi.org/10.1371/journal.pmed.1003436.t005
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to 1.40], p-value<0.001, RD 1,589/10,000 [95% CI 1,305/10,000 to 1,872/10,000], I2 89%). The
use of oxytocin was overall higher in SWEPIS, 65.7% versus 52.4% compared with the INDEX
trial 26.6% versus 10.9% (S3 Table).
There were 10.5% (240/2,281) cesarean deliveries in the IOL group versus 10.7% (245/
2,280) in the expectant management group (RR 0.98 [95% CI 0.83 to 1.16], p-value 0.81, RD
−22/10,000 [95% CI −201/10,000 to 157/10,000], I2 0%). Uterine hyperstimulation was not reg-
istered as such, but there was no increase in cesarean delivery after IOL compared to expectant
management, and there was no difference between the groups with respect to the indication
for cesarean delivery.
Maternal secondary outcomes
The maternal outcomes are presented in Table 6. Use of pain treatment (epidural/spinal or
opiates) was significantly higher in the IOL group compared to the expectant management
Table 6. Maternal outcomes in the population included in the IPD-MA.
Variable IOL group (n = 2,281) EM group
(n = 2,280)






1,153 (50.5) 1,058 (46.4) 1.09 (1.03; 1.16) 0.005 414 (125; 703) 0 0.85
Use of epidural anaesthesia 998 (43.8) 906 (39.7) 1.10 (1.03; 1.17) 0.006 400 (122; 678) 0 0.50
Use of opiates 184 (8.1) 173 (7.6) NE NE NE NE NE
Fever during labour 177 (7.8) 151 (6.6) 1.17 (0.95; 1.44) 0.14 114 (−96; 195) 0 0.66
Antibiotics during labour 296 (13.0) 297 (13.0) 0.99 (0.85; 1.15) 0.88 −6 (−197; 185) 62 0.11
Therapy 128 (5.6) 104 (4.6) 1.23 (0.96; 1.58) 0.11 105 (−22; 232) 0 0.62
Prophylaxis 168 (7.4) 193 (8.5) 0.87 (0.71; 1.05) 0.15 −111 (−264; 43) 30 0.23
Episiotomy‡ 328 (14.4) 335 (14.7) 0.97 (0.85; 1.11) 0.71 −30 (−226; 166) 0 0.53
Perineal lacerations III and IV§ 68 (3.0) 81 (3.6) 0.84 (0.61; 1.15) 0.28 −57 (−160; 46) 0 0.71
Postpartum haemorrhage (>1,000 ml)¶ 208 (9.1) 204 (9.0) 0.98 (0.82; 1.17) 0.86 17 (−149; 184) 70 0.067
Postpartum haemorrhage (>2,000 ml)¶ 42 (1.8) 34 (1.5) 1.23 (0.79; 1.93) 0.36 35 (−39; 109) 0 0.56
Retained placenta (all) 93 (4.1) 90 (3.9) 1.03 (0.78; 1.37) 0.82 13 (−101; 127) 10 0.29
Retained placenta with haemorrhage
(>1,000 ml)
62 (2.7) 61 (2.7) 1.02 (0.72; 1.44) 0.93 4 (−90; 98) 0 0.91
Retained placenta with haemorrhage
(�1,000 ml)
31 (1.4) 29 (1.3) 1.07 (0.65; 1.77) 0.80 9 (−57; 75) 63 0.10
Hypertensive disorders| 26 (1.1) 66 (2.9) 0.39 (0.25; 0.61) <0.001 −176 (−257; −94) 0 0.39
Maternal venous thromboembolism 0 (0.0) 1 (0.0) NE NE NE NE NE
Maternal admission to intensive care unit 5 (0.2) 2 (0.1) 2.50 (0.49; 12.86) 0.27 13 (−10; 36) 0 NE
Maternal death 0 (0.0) 0 (0.0) NE NE NE NE NE
Values are numbers (percentages) unless stated otherwise. RR is adjusted for RCT.
� In the INDEX trial, a combination of epidural and opiates was possible.
‡ With and without perineal lacerations III and IV.
§ With and without episiotomy.
¶ Based on measured blood loss and not ICD-10 codes reported.
| Hypertensive disorders of pregnancy including eclampsia and HELLP.
CI, confidence interval; EM, expectant management; HELLP, haemolysis, elevated liver enzymes, and a low platelet count; ICD-10, International Classification of
Diseases 10th Revision; INDEX, INDuction of labour at 41 weeks versus a policy of EXpectant management until 42 weeks; IOL, induction of labour; IPD-MA,
individual participant data meta-analysis; NE, not estimated due to 0 events in both arms in 1 or both trials; RD, risk difference; RCT, randomised controlled trial; RR,
relative risk.
https://doi.org/10.1371/journal.pmed.1003436.t006
PLOS MEDICINE Induction of labour at 41 weeks or expectant management until 42 weeks
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003436 December 8, 2020 16 / 25
group (50.5% [1,153/2,281] versus 46.4%, [1,058/2,280], RR 1.09 [95% CI 1.03 to 1.16], p-value
0.005, RD 414/10,000 [95% CI 125/10,000 to 703/10,000], I2 0%). Opiates during delivery were
only used in the INDEX trial.
The occurrence of hypertensive disorders of pregnancy was lower in the IOL than in the
expectant management group (1.1% [26/2,281] versus 2.9% [66/2,280], RR 0.39 [95% CI 0.25
to 0.61], p-value<0.001, RD −176/10,000 [95% CI −257/10,000 to −94/10,000], I2 0%, NNT 57
[95% CI 39 to 106]). There were no differences in severe morbidity, such as perineal lacera-
tions III and IV, postpartum haemorrhage, and rare events such as venous thromboembolism.
Subgroup analysis
The subgroup analysis on the primary composite outcome and cesarean delivery is presented
in Fig 2 and in S5 Table. The prespecified analysis on the primary composite outcome showed
a significant difference in the treatment effect according to parity (p = 0.01 for interaction).
The risk of adverse composite perinatal outcome in the IOL group versus the expectant man-
agement group was significantly decreased for nulliparous women (0.3% [4/1,219] versus 1.6%
[20/1,264], RR 0.20 [95% CI 0.07 to 0.60], p-value 0.004, RD −127/10,000 [95% CI −204/10,000
to −50/10,000], I2 0%, NNT 79 [49 to 201]), but not for multiparous women (0.6% [6/1,062]
versus 0.3% [3/1,016], RR 1.93 [95% CI 0.48 to 7.72], p-value 0.35, RD 27 [95% CI −29/10,000
to 84/10,000], I2 55%).
There was no significant difference in the treatment effect on the primary composite out-
come according to maternal age (<35 years and�35 years) and BMI (<30 and�30) (p = 0.45
and p = 0.62, respectively, for interaction).
The post hoc subgroup analysis on fetal sex had a p-value for interaction of 0.1 on the pri-
mary composite outcome. In boys, the composite outcome in the IOL group versus the expec-
tant management group occurred in 0.4% (5/1,228) versus 1.5% (18/1,194), (RR 0.28 [95% CI
0.10 to 0.75], p-value 0.01, RD −110/10,000 [95% CI −187/10,000 to −33/10,000], I2 0%) and in
girls in 0.5% (5/1,053) versus 0.5% (5/1,086), (RR 1.05 [95% CI 0.30 to 3.72], p-value 0.96, RD
2/10,000 [95% CI −56/10,000 to 59/10,000], I2 0%).
Because of the low perinatal mortality rate (0.2%, n = 9), no interaction analysis on mortal-
ity could be performed. Perinatal mortality according to subgroups is presented in S5 Table. In
nulliparous women, perinatal mortality occurred in 0% (0/1,219) in the IOL group versus
0.9% (7/1,264) in the expectant management group. In multiparous women, the correspond-
ing figures were 0.1% (1/1,062) versus 0.1% (1/1,016).
There was no significant difference in the treatment effect on cesarean delivery according
to parity, maternal age, or BMI (p-value for interaction 0.88, 0.07, and 0.32, respectively)
(Fig 2, S5 Table). The rate of cesarean delivery in nulliparous women was 18.0% (219/1,219) in
the IOL group and 17.9% (226/1,264) in the expectant management group (RR 1.01 [95% CI
0.85 to 1.19], p-value 0.95). Corresponding rates for multiparous women were 2.0% (21/1,062)
and 1.9% (19/1,016) (RR 1.05 [95% CI 0.57 to 1.95], p-value 0.87).
For other outcomes, there were no significant interaction effects for parity, except for use of
oxytocin. This was used more frequently in nulliparous women, 76% in the IOL group versus
65% in the expectant management group, and corresponding rates for multiparous women
were 49% versus 26% (p-value for interaction <0.001) (S5 Table).
Discussion
Summary of evidence
Overall, we found in this IPD-MA that IOL in women with an uncomplicated pregnancy at 41
weeks reduced the incidence of severe adverse perinatal outcome as compared with expectant
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Fig 2. Prespecified and post hoc subgroup analysis on (A) primary outcome: severe adverse perinatal outcome and (B)
cesarean delivery. �Including perinatal mortality, Apgar<4 at five minutes, HIE II-III, intracranial haemorrhage, neonatal
convulsions, MAS, obstetric brachial plexus injury, and mechanical ventilation within 72 hours. BMI, body mass index; CI,
confidence interval; HIE, hypoxic ischemic encephalopathy; MAS, meconium aspiration syndrome.
https://doi.org/10.1371/journal.pmed.1003436.g002
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management until 42 weeks from 1.0% to 0.4%. The NNT to avoid one of these events is 175
(95% CI 94 to 1,267). The risk of perinatal death was reduced from 0.4% to 0.04% after IOL at
41 weeks with an NNT of 326 (95% CI 177 to 2,014). Also, the risk for an infant to be treated
in neonatal care for four or more days was lower in the IOL group (NNT 103 [95% CI 59 to
385]). Cesarean delivery or operative vaginal delivery rates were comparable, just as most
important maternal adverse outcomes. The low rate of cesarean delivery reflects the low-risk
population of this IPD-MA. The rate of hypertensive disorders of pregnancy was found to be
lower in the IOL group with a NNT of 57 (95% CI 39 to 106).
In the subgroup analysis, we found that nulliparous women had a significantly reduced risk
of severe adverse perinatal outcome after IOL at 41 weeks compared with expectant manage-
ment until 42 weeks. The results indicate that infants of low-risk nulliparous women reaching
41 weeks of pregnancy will probably benefit from IOL at 41 weeks. For infants of low-risk mul-
tiparous women, the incidence of a severe adverse perinatal outcome is low. It is not clear if
they would benefit from IOL or not. In this IPD-MA, we lack the power to detect a difference
in multiparous women regarding severe adverse perinatal outcome, but also with an adequate
sample size, the NNT or to harm would probably be high. An explanation of the lower inci-
dence of adverse outcomes in multiparous women might be that women with previous cesar-
ean delivery were excluded from this IPD-MA. Furthermore, multiparous pregnant women at
41 weeks are probably women without major risk factors following from a previous pregnancy.
However, there may also be a true difference in risk between nulliparous and multiparous
women. The fact that infants of nulliparous women are at increased risk of adverse outcomes
in late-term pregnancy is in agreement with some but not all previous studies [28–30].
In the post hoc subgroup analysis on fetal sex, we found that the boys, rather than girls,
might benefit from IOL regarding the composite severe adverse perinatal outcome. However,
perinatal mortality did not differ by fetal sex; it occurred in five boys and four girls in our
IPD-MA.
The overall better outcome for IOL in our IPD-MA is in line with the latest Cochrane
review on IOL at or beyond term; however, no difference between parity was found [9]. The
increased risk of stillbirth with advancing gestational age is also shown in a recent large MA of
cohort studies by Muglu and colleagues [1]. Several large observational studies are also in line
with our findings [31,32]. However, other observational studies are not [33,34]. The Cochrane
reviews included RCTs with different time frames of comparison, and most RCTs had upper
limits of expectant management that went far beyond 42 weeks, which could at least partly
explain the higher risk of perinatal mortality with a policy of expectant management [8,9].
Strengths and limitations
IPD-MA is believed to be the preferred design for a systematic review of trials [35]. Our
IPD-MA included two recently published large RCTs carried out in two high-income coun-
tries with a study population reflecting the general population in each country. Both RCTs
excluded complicated pregnancies. Furthermore, the two countries, according to the Organi-
sation for Economic Co-operation and Development, are comparable in life expectancy, level
of education, perinatal mortality, and cesarean delivery. The overall similarity between the
RCTs enabled us to redefine a primary composite outcome that more accurately reflects seri-
ously affected neonates. We changed from Apgar<7 to Apgar <4 at five minutes because it is
associated with an increased risk of long-term adverse neonatal outcome and replaced NICU
admission by clearly diagnosed severe neonatal illness and severe complications because
NICU admission criteria in Sweden and the Netherlands are not comparable [21]. In addition,
the results of this IPD-MA are likely to be applicable to high-income countries due to the
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equivalence in healthcare status in the included trials but less applicable to low- or middle-
income countries. The heterogeneity between trials for most outcomes was low. Only for one
important outcome (Apgar score) heterogeneity was considerable.
Risk of bias assessed by the authors themselves may be considered as not independent; how-
ever, the low risk of bias is in agreement with the assessment of the independent reviewers in
the Cochrane 2020 updated review of Middleton and colleagues. [9].
There are a few issues, both in the SWEPIS trial and in the INDEX trial, which we would
like to highlight. In both trials, only low-risk women were included, and women with former
cesarean delivery or other major uterine surgery were excluded. Thus, how to advise these
women is still unclear. The SWEPIS trial was stopped early due to safety reasons; therefore, the
magnitude of the risk on perinatal death could be affected and may be overestimated also con-
sidering the difference in perinatal mortality rate between the SWEPIS and INDEX trial. Addi-
tionally, there was a discrepancy between the enrolment procedure of eligible low-risk women
in different centres. In the Stockholm region, inclusion was performed after a routine ultraso-
nographic assessment, including measurement of fetal abdominal diameter and amniotic
fluid, but at other centres, this was not performed routinely because it was not mandatory in
the study protocol. One could argue that the women included in the Stockholm region (41% of
all inclusions) were selected excluding women with fetuses at increased risk of adverse out-
come. Perinatal mortality did not occur in the expectant management group in Stockholm
centres (0/557; 0.0%), whereas in the other centres, there were six cases (6/822; 0.7%). How-
ever, there is currently insufficient evidence that routine surveillance with ultrasonographic
assessment in late term in order to detect fetuses at risk reduces perinatal mortality [36–39].
In a Swedish retrospective study, a reduction in SGA but no reduction in rates of composite
perinatal mortality and morbidity or stillbirth was found with routine ultrasound at 41 weeks
compared with indicated ultrasound [38]. Thus, whether the use of routine ultrasonographic
assessment at 41 weeks affected the outcome is difficult to determine. Furthermore, it reflects
the real clinical situation in Sweden regarding the management of prolonged pregnancy
and therefore probably increases the generalisability of the SWEPIS trial to the Swedish
population.
In both the SWEPIS and INDEX trials, fetal surveillance was performed according to local
protocol between 41 and 42 weeks. This could also be considered as a strength, rather than a
limitation, because it increases external validity of these pragmatic trials. In the SWEPIS trial,
it usually included an antenatal visit performed by a midwife with a clinical assessment and
auscultation of fetal heart rate. In the INDEX trial, it generally included clinical assessment
and assessment of the fetus with ultrasound, cardiotocography, and extra checks between 41
and 42 weeks [40]. This could be reflected in the higher rate of medical inductions for fetal and
maternal reasons between 41 and 42 weeks in the INDEX expectant management group com-
pared with the expectant group of the SWEPIS trial, though whether this contributed to a
lower perinatal mortality rate is unknown and makes us aware that further studies are needed
to evaluate the effect of screening regimes in late-term pregnancy.
In the INDEX trial, randomisation was not stratified by parity, which resulted in a small dif-
ference in distribution of nulliparous women between the groups (slightly higher rate in the
expectant management group), though after adjustment for parity similar, results were shown.
In addition, due to the healthcare system, a discrepancy between the IOL and expectant man-
agement group regarding level of care was present. All induced women were treated in an
obstetrician-led secondary care setting, while a large proportion of the women in the expectant
management group started their delivery in midwifery-led primary care including home
births. This might be considered as performance bias, but several studies have shown that the
level of care does not seem to influence the delivery outcome. Women at risk of adverse
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perinatal or maternal outcome are referred to secondary care (hospital); this risk selection is
on the basis of the Dutch obstetric care system [41–44]. Also, all babies in the expectant man-
agement group with adverse outcome were born in secondary care after referral before or dur-
ing delivery.
Furthermore, for our combined IPD-MA, a limitation is the low number of included
women (n = 5,161) compared with the recent Cochrane review (n = 12,479). However, none of
the trials except the Gelisen and the INDEX trials in the Cochrane review fulfilled our inclusion
criteria for gestational age. Including IPD from trials with induction before or after 41 weeks
and an expectant management policy beyond 42 weeks would have caused methodological
problems such as selection bias.
Finally, due to the few RCTs eligible for this IPD-MA, the possibility of assessing severe
adverse perinatal outcomes with few events and subgroup analysis was limited.
Conclusions and implications
In this study, we found that, overall, IOL at 41 weeks improved perinatal outcome compared
with expectant management until 42 weeks without increasing the cesarean delivery rate. This
benefit is shown only in nulliparous women, whereas for multiparous women, the incidence of
mortality and morbidity was too low to demonstrate any effect. The magnitude of risk reduc-
tion of perinatal mortality remains uncertain. Women with pregnancies approaching 41 weeks
should be informed on the risk differences according to parity so that they are able to make an
informed choice for IOL at 41 weeks or expectant management until 42 weeks.
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